| Literature DB >> 34894994 |
Pien Wolters1, G A Holtman1, A A H Weghorst1, M Knoester2, M Y Berger1.
Abstract
BACKGROUND: Rotavirus is a common cause of acute gastroenteritis in young children in the Netherlands, where rotavirus vaccination has not yet been implemented.Entities:
Keywords: After-hours care; faeces/virology; gastroenteritis/virology; paediatrics; primary care
Mesh:
Year: 2021 PMID: 34894994 PMCID: PMC8741236 DOI: 10.1080/13814788.2021.2011205
Source DB: PubMed Journal: Eur J Gen Pract ISSN: 1381-4788 Impact factor: 1.904
Figure 1.Flowchart of patient selection.
Baseline characteristics of the total cohort, included children, excluded children and children included in the trial.
| Characteristics | Total cohort | Included | Excluded | Trial |
|---|---|---|---|---|
| Number, | 201 | 75 | 126 | 191 |
| Gender (male), | 99 (49.3) | 34 (45.3) | 65 (51.6) | 92 (48.3) |
| Age in years, median (IQR) | 1.5 (0.9–2.1) | 1.5 (0.9–2.0) | 1.6 (0.9–2.3) | 1.5 (0.9–2.2) |
| Age categories | ||||
|
| 52 (25.9) | 19 (25.3) | 33 (26.2) | 52 (27.2) |
|
| 149 (74.1) | 56 (74.7) | 93 (73.8) | 139 (72.8) |
| Vomiting at presentation | ||||
|
| 48.0 (24.0–72.0) | 24.0 (1.8–72.0) | 48.0 (24.0–72.0) | 48.0 (24.0–72.0) |
|
| 4.0 (2.0–8.0) | 2.0 (1.0–4.0) | 4.0 (2.0–8.0) | 5.0 (4.0–10.0) |
| Diarrhoea at presentation | ||||
|
| 72.0 (48.0–96.0) | 48.0 (17.0–96.0) | 48.0 (0.0–96.0) | 24.0 (0.0–72.0) |
|
| 4.0 (2.0–6.0) | 3.0 (2.0–6.0) | 3.0 (0.0–4.0) | 2.0 (0.0–0.5) |
| Fever at presentation, | 51 (25.4) | 27 (36.0) | 24 (19.0) | 49 (25.7) |
| Referral to secondary care at presentation, n (%)d | 11 (5.5) | 4 (5.3) | 7 (5.6) | 9 (4.7) |
aDuration of vomiting and diarrhoea is the duration of symptoms from start to presentation at the primary care OOH and included all children.
bNumbers of vomiting and diarrhoeal episodes in the previous 24 h included all children.
cFever was defined as a documented temperature of ≥ 38.0 °C.
dReferral to secondary care at presentation was defined as direct referral from the primary care OOH service to secondary care.
IQR = interquartile range.
Prevalence different pathogens and corresponding cycle threshold values (N = 75).
| Subgroups |
| Rotavirus | Adenovirus | Astrovirus | Enterovirus | Norovirus | Sapovirus |
|---|---|---|---|---|---|---|---|
| All children, | 75 | 49 (65.3) (53.5–76.0) | 32 (42.7) (31.3–54.6) | 8 (10.7) (4.7–19.9) | 23 (30.7) (20.5–42.4) | 17 (22.7) (13.8–33.8) | 25 (33.3) (22.9–45.2) |
| Children aged 6–12 months, | 19 | 10 (52.6) (28.9–75.6) | 9 (47.4) (24.4–71.1) | 2 (10.5) (1.3–33.1) | 7 (36.8) (16.3–61.6) | 6 (31.6) (12.6–56.6) | 4 (21.1) (6.1–45.6) |
| Children age | 56 | 39 (69.6) (55.9–81.2) | 23 (41.1) (28.1––55.0) | 6 (10.7) (4.0–21.9) | 16 (28.6) (17.3–42.2) | 11 (19.6) (10.2–32.4) | 21 (37.5) (24.9–51.5) |
| Ct value median | 16.0 | 30.5 | 21.5 | 29.0 | 21.0 | 25.0 | |
| Ct value range | 10–37 | 4–38 | 8–33 | 13–38 | 10–37 | 10–35 | |
| Ct value categories | |||||||
| <20, | 37 (75.5) | 5 (15.6) | 4 (50.0) | 7 (30.4) | 8 (47.1) | 4 (16.0) | |
| 20–30, | 11 (22.4) | 11 (34.4) | 3 (37.5) | 8 (34.8) | 3 (17.6) | 17 (68.0) | |
| >30, | 1 (2.0) | 16 (50.0) | 1 (12.5) | 8 (34.8) | 6 (35.3) | 4 (16.0) |
The cycle threshold (Ct) was used to quantify the viral load, with lower values indicating a higher load. There were no significant differences between age groups.
aPercentages are calculated with total amount of children with each specific virus infection as denominator.
Differences between pathogens and factors related to the course of acute gastroenteritis.
| Outcome |
| Total | Rotavirus | No rotavirus | |
|---|---|---|---|---|---|
| Severe course of acute gastroenteritis, | 71 | 31/71 (43.7) | 20/47 (42.6) | 11/24 (45.8) | 0.81 |
| Referral at baseline or during follow-up, | 54 | 8/54 (14.8) | 5/33 (15.2) | 3/21 (14.3) | 0.93 |
STROBE Statement—Checklist of items that should be included in reports of .
| Item No | Recommendation | Page No | |
|---|---|---|---|
| Title and abstract | 1 | ( | 1 (Title page document) |
| ( | 1 (Manuscript document) | ||
| Introduction | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 2/3 |
| Objectives | 3 | State-specific objectives, including any prespecified hypotheses | 3 |
| Methods | |||
| Study design | 4 | Present key elements of study design early in the paper | 3 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 |
| Participants | 6 | ( | 4 |
| ( | n/a | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5/6 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of assessment methods (measurement). Describe comparability of assessment methods if there is more than one group | 4/5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4 |
| Study size | 10 | Explain how the study size was arrived at | 6 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 6/7 |
| Statistical methods | 12 | ( | 6/7 |
| ( | 6/7 | ||
| ( | 6/7 | ||
| ( | 6/7 | ||
| ( | n/a | ||
| Results | |||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 7 |
| (b) Give reasons for non-participation at each stage | 7 | ||
| (c) Consider use of a flow diagram | See Flowchart | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders | 7 |
| (b) Indicate number of participants with missing data for each variable of interest | 7 | ||
| (c) Summarise follow-up time (e.g. average and total amount) | n/a | ||
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 8 |
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.